- Home
- LPTH vs TOVX Comparison
LPTH vs TOVX Comparison
Compare LPTH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- TOVX
- Stock Information
- Founded
- LPTH 1985
- TOVX 2001
- Country
- LPTH United States
- TOVX United States
- Employees
- LPTH N/A
- TOVX N/A
- Industry
- LPTH Semiconductors
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- TOVX Health Care
- Exchange
- LPTH Nasdaq
- TOVX Nasdaq
- Market Cap
- LPTH 128.3M
- TOVX 3.8M
- IPO Year
- LPTH 1996
- TOVX 2006
- Fundamental
- Price
- LPTH $3.08
- TOVX $0.44
- Analyst Decision
- LPTH Strong Buy
- TOVX Hold
- Analyst Count
- LPTH 3
- TOVX 1
- Target Price
- LPTH $4.67
- TOVX N/A
- AVG Volume (30 Days)
- LPTH 167.2K
- TOVX 1.6M
- Earning Date
- LPTH 05-15-2025
- TOVX 08-12-2025
- Dividend Yield
- LPTH N/A
- TOVX N/A
- EPS Growth
- LPTH N/A
- TOVX N/A
- EPS
- LPTH N/A
- TOVX N/A
- Revenue
- LPTH $33,626,969.00
- TOVX N/A
- Revenue This Year
- LPTH $19.58
- TOVX N/A
- Revenue Next Year
- LPTH $44.50
- TOVX N/A
- P/E Ratio
- LPTH N/A
- TOVX N/A
- Revenue Growth
- LPTH 2.59
- TOVX N/A
- 52 Week Low
- LPTH $1.04
- TOVX $0.40
- 52 Week High
- LPTH $4.42
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- LPTH 57.52
- TOVX 33.63
- Support Level
- LPTH $2.96
- TOVX $0.43
- Resistance Level
- LPTH $3.28
- TOVX $0.46
- Average True Range (ATR)
- LPTH 0.20
- TOVX 0.04
- MACD
- LPTH -0.01
- TOVX 0.02
- Stochastic Oscillator
- LPTH 60.00
- TOVX 15.54
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.